Video Experimental Relacionado
Updated: Sep 10, 2025
10:50
Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
Published on: May 1, 2019
14.8K
Avances en la farmacocinética poblacional de los anticuerpos monoclonales
Shouhua Mu1,2, Xiaojing Zhang1, Jingyan Jin1,2
1Pharmacy of the 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, China; and.
Therapeutic drug monitoring
|August 27, 2025
Resumen
Los modelos farmacocinéticos de población (PPK) son cruciales para la individualización de la terapia con anticuerpos monoclonales (mAb). Esta revisión destaca los estudios actuales de PPK sobre fármacos mAb, informando la práctica clínica y el monitoreo terapéutico de fármacos para mejorar la eficacia y la seguridad.
Área de la Ciencia:
- Farmacología
- Inmunología
- Desarrollo de drogas
Sus antecedentes:
- Los anticuerpos monoclonales (mAbs) son vitales en el tratamiento de tumores y enfermedades autoinmunes.
- La significativa variabilidad interindividual en la farmacocinética de mAb afecta a la eficacia y seguridad del fármaco.
- La administración individualizada de fármacos y el monitoreo terapéutico de fármacos son esenciales para optimizar los tratamientos de mAb.
Objetivo del estudio:
- Revisar los estudios farmacocinéticos de población (PPK) actuales sobre los fármacos de anticuerpos monoclonales (mAb).
- Proporcionar una referencia para la individualización clínica de la terapia con fármacos mAb.
Principales métodos:
- Búsqueda de literatura de PubMed y la Red de Conocimiento de China (2017-2024).
- Selección y revisión detallada de 30 artículos relevantes basados en títulos y resúmenes.
- El análisis final incluyó 15 artículos, con estudios adicionales relevantes procedentes de listas de referencia.
Principales resultados:
- Seis estudios utilizaron modelos de PPK establecidos para optimizar los regímenes de dosificación.
- Seis estudios se centraron en el establecimiento de modelos de PPK, lo que requiere estudios farmacodinámicos adicionales para la optimización del régimen.
- Dos estudios se encuentran actualmente en la fase de ensayo clínico para el desarrollo de fármacos mAb.
Conclusiones:
- Esta revisión sintetiza los avances actuales en la investigación de PPK para los fármacos mAb.
- Los hallazgos apoyan la individualización clínica de la terapia con fármacos mAb a través del modelado PPK.
- Destaca la importancia de los modelos PPK para el seguimiento terapéutico de fármacos y la medicina personalizada.
Videos de Conceptos Relacionados
01:12Analysis of Population Pharmacokinetic Data
382
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
382
01:29Drug Distribution: Plasma Protein Binding
6.6K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
6.6K
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
273
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
273
01:13Physiological Pharmacokinetic Models: Assumption with Protein Binding
91
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
91
01:19Nonlinear Pharmacokinetics: Overview
544
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
544
01:31Hybridoma Technology
15.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.3K